Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: A cost effectiveness analysis

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Pooran, Anil ^a,c   Booth, Helen ^b   Miller, Robert F ^a,b   Scott, Geoff ^b   Badri, Motasim ^c   Huggett, Jim F ^a   Rook, Graham ^a   Zumla, Alimuddin ^a,b   Dheda, Keertan ^a,b,c,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ISONIAZID;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HEALTH CARE COST; HUMAN; INFECTION RATE; INTERMETHOD COMPARISON; LIVER TOXICITY; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; TUBERCULIN TEST; TUBERCULOSIS; UNITED KINGDOM; CONTACT EXAMINATION; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; INCIDENCE; LUNG TUBERCULOSIS; MASS SCREENING; METABOLISM; METHODOLOGY; PREVALENCE;

CONTACT TRACING; COST-BENEFIT ANALYSIS; DECISION TREES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; INCIDENCE; INTERFERON-GAMMA; MASS SCREENING; PREVALENCE; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 77649325064     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-7     Document Type: Article

References (57)

1. Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med 2005, 11(3):195-202. 10.1097/01.mcp.0000158726.13159.5e, 15818179.
2. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of internal medicine 2007, 146(5):340-354.
3. Pai M, Riley LW, Colford JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004, 4(12):761-776. 10.1016/S1473-3099(04)01206-X, 15567126.
4. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of internal medicine 2008, 149(3):177-184.
5. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis 2006, 10(11):1192-1204.
6. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007, 131(6):1898-1906. 10.1378/chest.06-2471, 17565023.
7. National Institute for Health and Clinical Excellence Clinical diagnosis and management of tuberculosis, and measures for its prevention and control: Clinical Guideline 33. 2006, National Institute for Health and Clinical Excellence., http://guidance.nice.org.uk/CG33/costreport/
8. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54(RR-15):49-55.
9. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007, 131(5):1424-1434. 10.1378/chest.06-2728, 17494792.
10. Diel R, Wrighton-Smith P, Zellweger JP. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J 2007, 30(2):321-332. 10.1183/09031936.00145906, 17504793.
11. Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respiratory medicine 2009, 103(12):1838-1853. 10.1016/j.rmed.2009.07.008, 19682884.
12. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007, 11(1):16-26.
13. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006, 28(1):45-50. 10.1183/09031936.06.00005906, 16611659.
14. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006, 28(1):35-44. 10.1183/09031936.06.00011806, 16571615.
15. de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Archives of internal medicine 2009, 169(2):179-187. 10.1001/archinternmed.2008.524, 19171815.
16. Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, Morshed M, Brunham RC, Fitzgerald JM. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008, 12(12):1414-1424.
17. Taylor WC, Aronson MD, Delbanco TL. Should young adults with a positive tuberculin test take isoniazid?. Annals of internal medicine 1981, 94(6):808-813.
18. Bank of England Consumer Price Inflation Calculator, 1750 to 2008. Bank of England., http://www.bankofengland.co.uk/education/inflation/calculator/index1.htm
19. Control and Prevention of Tuberculosis in the United Kingdom: Code of practice 2000. Thorax 2000, 887-901. 1745632, 11050256.
20. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000, 161(3 Pt 1):780-789.
21. Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995, 8(8):1384-1388. 10.1183/09031936.95.08081384, 7489806.
22. Weiseger RA. Isoniazid Hepatotoxicity. 2007, , http://www.emedicine.com/med/topic1193.htm
23. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982, 60(4):555-564. 2536088, 6754120.
24. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis 1988, 137(1):215-220.
25. Health Protection Agency Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2009. Health Protection Agency., http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1259152022594
26. Sahni R, Miranda C, Yen-Lieberman B, Tomford JW, Terpeluk P, Quartey P, Johnson LT, Gordon SM. Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?. Infect Control Hosp Epidemiol 2009, 30(2):197-199. 10.1086/593965, 19119939.
27. Bothamley GH, Rowan JP, Griffiths CJ, Beeks M, McDonald M, Beasley E, Bosch C, Feder G. Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless. Thorax 2002, 57(1):45-49. 10.1136/thorax.57.1.45, 1746167, 11809989.
28. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006, 6:47. 10.1186/1471-2334-6-47, 1434750, 16539718.
29. HPA Tuberculosis Program Board Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB): Interim HPA guidance. 2008, HPA Tuberculosis Program Board., http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1214808549127
30. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006, 367(9519):1328-1334. 10.1016/S0140-6736(06)68579-6, 16631911.
31. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004, 170(1):59-64. 10.1164/rccm.200402-179OC, 15059788.
32. Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005, 12(4):491-496. 1074386, 15817755.
33. Tsiouris SJ, Austin J, Toro P, Coetzee D, Weyer K, Stein Z, El-Sadr WM. Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. Int J Tuberc Lung Dis 2006, 10(8):939-941.
34. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173(8):927-931. 10.1164/rccm.200510-1563OC, 16424442.
35. Dheda K, Lalvani A, Miller R, Scott G, Booth H, Johnson M, Zumla A, Rook G. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005, 19:2038-2041. 10.1097/01.aids.0000191923.08938.5b, 16260914.
36. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004, 364(9452):2196-2203. 10.1016/S0140-6736(04)17592-2, 15610806.
37. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax 2000, 55(11):962-963. 10.1136/thorax.55.11.962, 1745633, 11050268.
38. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174(8):935-952. 10.1164/rccm.200510-1666ST, 17021358.
39. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003, 361(9364):1168-1173. 10.1016/S0140-6736(03)12950-9, 12686038.
40. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, Ewer K, Barnes PF. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005, 172(9):1161-1168. 10.1164/rccm.200505-748OC, 2718400, 16081545.
41. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001, 163(4):824-828.
42. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005, 24(8):529-536. 10.1007/s10096-005-1377-8, 16133410.
43. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001, 167(9):5217-5225.
44. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, Amicosante M, Girardi E. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005, 12(11):1311-1316. 1287767, 16275946.
45. Huebner RE, Schein MF, Bass JB. The tuberculin skin test. Clin Infect Dis 1993, 17(6):968-975.
46. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006, 28(1):24-30. 10.1183/09031936.06.00016906, 16611658.
47. Taylor Z. The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis 2000, 4(12 Suppl 2):S127-133.
48. Bass JB, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994, 149(5):1359-1374.
49. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000, (2):CD001363.
50. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991, 99(2):465-471. 10.1378/chest.99.2.465, 1824929.
51. Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993, 159(5):560-564. 1022345, 8279152.
52. Salpeter SR, Salpeter EE. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol 2004, 25(12):1056-1061. 10.1086/502343, 15636292.
53. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970, 26:28-106.
54. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999, 3(10):847-850.
55. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005, 25(6):1107-1116. 10.1183/09031936.05.00074004, 15929967.
56. UK Department of Health National tariff 2005-06. UK Department of Health., http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4091529
57. Curtis L. Unit costs of health and social care 2007. , http://www.pssru.ac.uk/pdf/uc/uc2007/uc2007.pdf